Research Analysts Offer Predictions for CymaBay Therapeutics Inc.’s Q1 2018 Earnings (CBAY)
CymaBay Therapeutics Inc. (NASDAQ:CBAY) – Equities research analysts at Leerink Swann issued their Q1 2018 EPS estimates for shares of CymaBay Therapeutics in a research report issued on Wednesday. Leerink Swann analyst J. Schwartz anticipates that the biopharmaceutical company will post earnings of ($0.19) per share for the quarter. Leerink Swann has a “Outperform” rating and a $12.00 price objective on the stock. Leerink Swann also issued estimates for CymaBay Therapeutics’ Q2 2018 earnings at ($0.21) EPS and Q3 2018 earnings at ($0.22) EPS.
CBAY has been the topic of several other research reports. Cantor Fitzgerald initiated coverage on shares of CymaBay Therapeutics in a research note on Tuesday, September 19th. They set an “overweight” rating and a $16.00 price target on the stock. Zacks Investment Research upgraded shares of CymaBay Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, September 18th. Piper Jaffray Companies reiterated a “buy” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a research note on Friday, October 27th. Ifs Securities cut shares of CymaBay Therapeutics from a “strong-buy” rating to an “outperform” rating in a research note on Friday, August 11th. Finally, SunTrust Banks, Inc. initiated coverage on shares of CymaBay Therapeutics in a research note on Friday, August 18th. They set a “buy” rating and a $15.00 price target on the stock. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $14.00.
ILLEGAL ACTIVITY WARNING: “Research Analysts Offer Predictions for CymaBay Therapeutics Inc.’s Q1 2018 Earnings (CBAY)” was published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.watchlistnews.com/research-analysts-offer-predictions-for-cymabay-therapeutics-inc-s-q1-2018-earnings-cbay/1695469.html.
CymaBay Therapeutics (NASDAQ CBAY) opened at $9.25 on Friday. CymaBay Therapeutics has a 12-month low of $1.46 and a 12-month high of $9.40. The company has a current ratio of 7.39, a quick ratio of 1.49 and a debt-to-equity ratio of 0.04.
CymaBay Therapeutics (NASDAQ:CBAY) last posted its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). During the same period in the previous year, the company earned ($0.25) earnings per share.
In related news, Director Carl Goldfischer sold 18,000 shares of CymaBay Therapeutics stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $8.66, for a total transaction of $155,880.00. Following the transaction, the director now owns 9,000 shares in the company, valued at approximately $77,940. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Kurt Von Emster sold 59,209 shares of CymaBay Therapeutics stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $9.27, for a total transaction of $548,867.43. Following the transaction, the director now owns 90,000 shares in the company, valued at approximately $834,300. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 397,209 shares of company stock worth $3,267,417. 15.10% of the stock is owned by corporate insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in CBAY. Renaissance Technologies LLC lifted its stake in shares of CymaBay Therapeutics by 97.6% during the 1st quarter. Renaissance Technologies LLC now owns 231,949 shares of the biopharmaceutical company’s stock valued at $997,000 after buying an additional 114,549 shares in the last quarter. LVM Capital Management Ltd. MI lifted its stake in shares of CymaBay Therapeutics by 100.0% during the 2nd quarter. LVM Capital Management Ltd. MI now owns 20,000 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 10,000 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in shares of CymaBay Therapeutics by 0.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 140 shares in the last quarter. Marshall Wace North America L.P. bought a new stake in CymaBay Therapeutics in the 2nd quarter valued at $242,000. Finally, Vanguard Group Inc. increased its holdings in CymaBay Therapeutics by 20.7% in the 2nd quarter. Vanguard Group Inc. now owns 991,633 shares of the biopharmaceutical company’s stock valued at $5,712,000 after acquiring an additional 170,126 shares during the last quarter. Institutional investors own 25.75% of the company’s stock.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.